FDA Drugs (New Approvals & NDA)Original article
FDA Virtual Workshop on Digital Health Technologies and Statistical Considerations for Digitally-Derived Endpoints in Clinical Trials - 08/27/2026
Neutral
AI Analysis
Summary
The FDA is hosting a free virtual public workshop on August 27, 2026, convened with the Duke-Margolis Institute to discuss statistical considerations for digitally-derived endpoints in clinical trials for drug and biological products.
Importance:2/10
Sentiment:
0.00
FDA workshopdigital healthdigitally-derived endpointsclinical trialsregulatory guidance
Related Companies
Read the original article
Published by FDA Drugs (New Approvals & NDA) on July 21, 2026 5:20 PM